In renal cell carcinoma, the combination of IPI+anti-PD-1 was associated with better response (objective response rate [ORR] 42% versus 27%) and PFS (median PFS, 11.6 versus 8.4 months) compared to sunitinib in patients with intermediate or poor risk renal cell carcinoma (RCC) in the first line setting (41). The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.